Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182048 | 0.87 | ANO1 (0.74) | ANO1 | |
| SCHEMBL12756789 | 0.85 | MEN1 (0.41) | ANO1MAPTMEN1KMT2AALOX15 | |
| SCHEMBL12414128 | 0.83 | CASP3 (0.46) | ANO1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL7959514 | 0.82 | MAPT (0.42) | ANO1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12271375 | 0.80 | ANO1 (0.59) | ANO1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7955126 | 0.80 | ANO1 (0.59) | ANO1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14685860 | 0.77 | ANO1 (0.52) | ANO1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12414150 | 0.75 | ANO1 (0.75) | ANO1MAPTSMN1; SMN2RAB9AMEN1 | |
| SCHEMBL2180097 | 0.75 | ANO1 (0.53) | ANO1 | |
| SCHEMBL2182520 | 0.74 | ANO1 (0.50) | ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010025295-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885MAPT 1478/4885SMN1; SMN2 854/4885 |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885MAPT 1478/4885SMN1; SMN2 854/4885 |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885MAPT 1478/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.